Understanding genetic cancer predisposition has taken a significant step forward with new insights that could reshape screening recommendations for thousands of families worldwide. While CDH1 mutations have dominated hereditary gastric cancer research, this comprehensive analysis reveals that CTNNA1 gene variants create their own distinct cancer risk profile with important therapeutic implications.
Researchers analyzed 1,308 individuals from 351 families carrying CTNNA1 variants alongside 37,428 controls, discovering that truncating variants pose an eightfold higher diffuse gastric cancer risk compared to non-truncating variants. The mechanism involves nonsense-mediated mRNA decay that eliminates truncated transcripts and depletes αE-catenin protein levels in tumor cells. Using CRISPR gene editing and fruit fly models, scientists confirmed these truncating variants are functionally null mutations, while non-truncating variants retain partial activity.
These findings challenge current clinical approaches that treat all CTNNA1 variants similarly. The data suggests truncating variant carriers face substantial cancer risks warranting intensive surveillance, while non-truncating carriers may need less aggressive monitoring. Importantly, CTNNA1-associated risks remain considerably lower than those seen with CDH1 mutations - fivefold lower for gastric cancer and eightfold lower for lobular breast cancer. This risk stratification could prevent unnecessary prophylactic surgeries while ensuring appropriate screening for high-risk individuals. The research establishes a foundation for precision medicine approaches in hereditary cancer syndromes, moving beyond one-size-fits-all genetic counseling toward variant-specific risk assessment and management strategies.